Biodexa Pharmaceuticals Plc ADR (BDRX)

$3.24 -0.06 (-1.82%)
Market Cap 6.59M
Revenue (ttm) 0.00
Net Income (ttm) -8.42M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.01
Volume 21,000
Avg Vol 546,613
Day's Range N/A - N/A
Shares Out 2.00M
Stochastic %K 4%
Beta 1.11
Analysts Strong Buy
Price Target $35.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
luckyluke17
luckyluke17 Apr. 29 at 2:28 AM
$BDRX doesn't even mention eRapa fast tracked in phase 3 and enrolled first patient over 4 months ago (reported). Nanoparticle delivery system to improve absorption and stability in rapamycin. Rapamycin is a proven drug for anti tumor and anti proliferation. Going under the radar her majorly
0 · Reply
luckyluke17
luckyluke17 Apr. 28 at 4:45 PM
$BDRX are you ready?!
0 · Reply
FlyingTargets
FlyingTargets Apr. 27 at 8:34 PM
$BYND $OPEN $BDRX recent ones
0 · Reply
luckyluke17
luckyluke17 Apr. 27 at 10:48 AM
$BDRX no one still? Holla if you're here!
2 · Reply
luckyluke17
luckyluke17 Apr. 25 at 2:25 AM
$BDRX 👀
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 24 at 2:24 PM
$PSTV $ENVB $BDRX
0 · Reply
luckyluke17
luckyluke17 Apr. 24 at 1:48 PM
$BDRX sitting tight @Love_To_Learn
0 · Reply
luckyluke17
luckyluke17 Apr. 23 at 8:06 PM
$BDRX @Love_To_Learn with short interest data set to be publicized tomorrow, is this part of MJ theme
1 · Reply
luckyluke17
luckyluke17 Apr. 23 at 11:30 AM
$BDRX @Love_To_Learn the silence here is deafening
0 · Reply
Tahabder
Tahabder Apr. 21 at 5:14 PM
$GNPX It will take time to move and not good move come to $BDRX
0 · Reply
Latest News on BDRX
Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Apr 2, 2026, 8:30 AM EDT - 27 days ago

Biodexa Announces Partnership with Syngene To Manufacture MTX240 GMP Clinical Trial Supplies

Preliminary Results for the Year Ended 31 December 2025

Mar 27, 2026, 5:00 PM EDT - 4 weeks ago

Preliminary Results for the Year Ended 31 December 2025

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

Mar 23, 2026, 8:30 AM EDT - 5 weeks ago

Biodexa Launches Global Early Access Program for eRapa for FAP Patients Through Strategic Partnership with Tanner Pharma Group

ADR Ratio Change

Mar 18, 2026, 5:00 PM EDT - 6 weeks ago

ADR Ratio Change

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Mar 9, 2026, 8:30 AM EDT - 7 weeks ago

Biodexa Announces Support for Life's a Polyp Foundation First U.S. Patient Advocacy Group for FAP Patients

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Feb 19, 2026, 7:30 AM EST - 2 months ago

Biodexa Licenses Phase 1 Ready Drug Candidate from Otsuka for Rare Stomach Cancer

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Feb 4, 2026, 8:30 AM EST - 3 months ago

Biodexa Announces Exclusive License of Otsuka's OPB-171775, a potent Phase 1 ready Molecular Glue for GIST

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Jan 5, 2026, 8:30 AM EST - 4 months ago

Appointment of Fiona Sharp to the Board as Chief Financial Officer and Company Secretary

Biodexa Announces Pricing of $10 Million Public Offering

Dec 18, 2025, 8:30 AM EST - 4 months ago

Biodexa Announces Pricing of $10 Million Public Offering

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Dec 1, 2025, 8:30 AM EST - 5 months ago

Biodexa Announces Enrolment of First European Patients into Pivotal Phase 3 Serenta Trial in FAP

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Nov 24, 2025, 8:30 AM EST - 5 months ago

Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Nov 3, 2025, 8:30 AM EST - 6 months ago

Biodexa Announces Approval of CTA in Europe for Phase 3 Serenta Trial in FAP First European patient expected to be enrolled in 4Q 2025 Addressable US - European Market Put at $7 Billion

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Oct 6, 2025, 8:30 AM EDT - 7 months ago

Biodexa to Host Breakfast Symposium on FAP Mechanisms and Chemoprevention Trial Issues at CGA – IGC Conference on October 11, 2025

Interim results for the six months ended June 30, 2025

Sep 12, 2025, 8:30 AM EDT - 8 months ago

Interim results for the six months ended June 30, 2025

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Sep 8, 2025, 7:00 AM EDT - 8 months ago

Biodexa Moves Into Phase 3 With eRapa For FAP With First Patients Enrolled

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

ADR Ratio Change Effective

Jul 31, 2025, 9:30 AM EDT - 9 months ago

ADR Ratio Change Effective

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Jul 28, 2025, 7:00 AM EDT - 9 months ago

How Biodexa Is Racing To Get Its Phase 3 Program in FAP Under Way And Gain First-Mover Advantage in a $7Bn Addressable Market

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jul 14, 2025, 8:30 AM EDT - 10 months ago

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 10 months ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 11 months ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 11 months ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 11 months ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 11 months ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 11 months ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 1 year ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 1 year ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 1 year ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 1 year ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 1 year ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 1 year ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 1 year ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 1 year ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 1 year ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 1 year ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 1 year ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

luckyluke17
luckyluke17 Apr. 29 at 2:28 AM
$BDRX doesn't even mention eRapa fast tracked in phase 3 and enrolled first patient over 4 months ago (reported). Nanoparticle delivery system to improve absorption and stability in rapamycin. Rapamycin is a proven drug for anti tumor and anti proliferation. Going under the radar her majorly
0 · Reply
luckyluke17
luckyluke17 Apr. 28 at 4:45 PM
$BDRX are you ready?!
0 · Reply
FlyingTargets
FlyingTargets Apr. 27 at 8:34 PM
$BYND $OPEN $BDRX recent ones
0 · Reply
luckyluke17
luckyluke17 Apr. 27 at 10:48 AM
$BDRX no one still? Holla if you're here!
2 · Reply
luckyluke17
luckyluke17 Apr. 25 at 2:25 AM
$BDRX 👀
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 24 at 2:24 PM
$PSTV $ENVB $BDRX
0 · Reply
luckyluke17
luckyluke17 Apr. 24 at 1:48 PM
$BDRX sitting tight @Love_To_Learn
0 · Reply
luckyluke17
luckyluke17 Apr. 23 at 8:06 PM
$BDRX @Love_To_Learn with short interest data set to be publicized tomorrow, is this part of MJ theme
1 · Reply
luckyluke17
luckyluke17 Apr. 23 at 11:30 AM
$BDRX @Love_To_Learn the silence here is deafening
0 · Reply
Tahabder
Tahabder Apr. 21 at 5:14 PM
$GNPX It will take time to move and not good move come to $BDRX
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 21 at 4:13 PM
$BDRX
0 · Reply
Tahabder
Tahabder Apr. 21 at 4:00 PM
$BDRX
0 · Reply
luckyluke17
luckyluke17 Apr. 21 at 2:47 PM
$BDRX 30k borrowed this morning down to 300, 600 returned to bring us to 900 shares available to borrow with a 238% borrow rate. Expensive 30K to short
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 21 at 2:33 PM
$BDRX bought dips
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 21 at 10:32 AM
$BDRX b nice to them
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 21 at 10:32 AM
$SLS now taking her to beud * clik $BDRX brought u friends beud
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 21 at 9:54 AM
$BDRX GOING HIGHER
2 · Reply
Love_To_Learn
Love_To_Learn Apr. 21 at 12:21 AM
$BDRX VERY IMPRESSED BY U BEUD U WERE VERY CALM AND RELAXED CONSISTENT NOT PSYCHO LIKE U REALLY R OK OK THERAPY BEEN WORKING
3 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 7:29 PM
$BDRX MANIPULATING YOU AROUND 4.42 IT WILL B FITTING TO USE IT FOR SLS $SLS SIT TIGHT $MAAS MANIPULATING U AFTER TAKING YOUR LUNCH MONEY !
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 7:27 PM
$BDRX USING U TO WIPE ALL OF SLS METADATA WHEN U HIT THEIR 4.42 ANOMALY $SLS SYNCHRONIZING
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 6:59 PM
$PSTV CODING 7.07 OLD ENVB AND BEUD $ENVB $BDRX CODING FOR MARKET !LETS GO !
1 · Reply
Love_To_Learn
Love_To_Learn Apr. 20 at 6:25 PM
$BDRX SORRY BEUD BEEN DISTRACTED ALL DAY U KNOW LARRY UP TIGHT NEEDS IS BOOKS BALANCED OR HE GOES BYE BYE LOL
0 · Reply